William Mallard on Muck Rack

William Mallard

Verified
Tokyo
As seen in: Reuters, MSN Australia, Business Insider, Daily Mail, Nature, Reuters Japan, The Daily Mirror, Yahoo Canada, Yahoo News Malaysia, Yahoo Singapore, News.com.au and
Tokyo-based editor @Reuters. Ex-@DowJones/@WSJ, Kyodo, @AJC. Atlanta boy in Japan for a right long while. 堪へ難キヲ堪へ忍ヒ難キヲ忍ヒ, y’all. He/his/僕
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with William

Contact William, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trump remains in excellent health, White House memo says

|
By Disha Mishra, William Mallard Verified
| Detroit News Verified
May 29, 2026, 11:49 p.m. ET President Donald Trump remains in excellent health, with strong cardiac, pulmonary, neurological and overall physical function, the White House said in a memo on Friday, citing results from a medical examination this week.
Open in Who Shared View Duplicates (143) Issue with article?

US probes Reid Hoffman group over funding lawsuits against Trump, source says

|
By Jacqueline Wong, Andrew Goudsward Verified, William Mallard Verified
| Westlaw Today Verified
WASHINGTON, May 29 (Reuters) - The U.S. Justice Department has opened an investigation into a group tied to billionaire Reid Hoffman over its partial funding of writer E. Jean Carroll's lawsuits against President Donald Trump, a person familiar with...
Open in Who Shared Issue with article?

Replimune gets third chance at US approval for skin cancer drug

|
By Shinjini Ganguli Verified, Mariam Sunny, William Mallard Verified
| Westlaw Today Verified
May 29 (Reuters) - Replimune said on Friday it plans to apply a third time for approval of its experimental skin cancer drug in the coming days after reaching an agreement with the U.S. regulator. Shares of the company rocketed 86% for the day to...
Open in Who Shared Issue with article?
See all 692 licensed articles (748 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified